To the Editor: We agree with Mead et al. that recent clinical studies support the routine clinical use of serum free light chain (FLC) measurements. The data suggest the use of laboratory FLC testing for the diagnosis and monitoring of nonsecretory myeloma and AL amyloidosis, as a prognostic marker ...